Bessemer Group Inc. Sells 658 Shares of Moderna, Inc. (NASDAQ:MRNA)

Bessemer Group Inc. reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 11.7% in the 4th quarter, Holdings Channel reports. The firm owned 4,962 shares of the company’s stock after selling 658 shares during the quarter. Bessemer Group Inc.’s holdings in Moderna were worth $206,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of Moderna in the 4th quarter valued at approximately $8,493,000. APG Asset Management N.V. grew its position in Moderna by 848.2% in the fourth quarter. APG Asset Management N.V. now owns 227,819 shares of the company’s stock valued at $9,148,000 after acquiring an additional 203,792 shares during the period. Advisory Services Network LLC raised its stake in Moderna by 543.1% during the fourth quarter. Advisory Services Network LLC now owns 19,603 shares of the company’s stock worth $815,000 after acquiring an additional 16,555 shares in the last quarter. Capula Management Ltd acquired a new position in Moderna during the fourth quarter worth $246,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Moderna by 225.7% during the fourth quarter. Renaissance Technologies LLC now owns 1,010,758 shares of the company’s stock valued at $42,027,000 after acquiring an additional 700,458 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Trading Down 4.0 %

Moderna stock opened at $25.19 on Thursday. The firm has a market capitalization of $9.74 billion, a P/E ratio of -2.71 and a beta of 2.23. The business has a 50-day moving average of $31.10 and a 200-day moving average of $40.37. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $170.47.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on MRNA shares. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Bank of America dropped their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday, February 11th. Citigroup initiated coverage on Moderna in a report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 target price on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. Finally, Barclays lowered Moderna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.